Dexpramipexole - Areteia Therapeutics
Alternative Names: BIIB-050; KNS-760704; RPPXLatest Information Update: 03 May 2024
At a glance
- Originator University of Virginia
- Developer Areteia Therapeutics; Biogen Idec; Knopp Biosciences; National Institute of Allergy and Infectious Diseases
- Class Amines; Antiasthmatics; Benzothiazoles; Neuroprotectants; Small molecules
- Mechanism of Action Antioxidants; Apoptosis inhibitors; Dopamine receptor agonists; Free radical scavengers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Asthma
- Phase II Amyotrophic lateral sclerosis; Hypereosinophilic syndrome
Most Recent Events
- 29 Apr 2024 Areteia Therapeutics initiates enrolment in a phase III EXHALE-5 trial for Asthma (In Adolescents, In Adults, In the elderly) in the US (NCT06388889)
- 03 Aug 2023 Updated efficacy data from the phase II EXHALE-1 trial in Asthma released by Areteia Therapeutics
- 27 Mar 2023 Phase-III clinical trials in Asthma (In adolescents, In adults, In the elderly) in Asia (PO) (Areteia Therapeutics website, October 2022)